Private Company Edition: Quarter-over-quarter increases in venture capital have been bolstered by fewer but larger rounds, like the recent $245m series A for Aiolos. Also, OrbiMed raised $4.3bn across three new VC funds, Rampart completed an $85m series A and Atom Bioscience raised an $83m series D. 

Seven international translational research bodies recommend five actions to help better prepare for future outbreaks. Plus an overview of recent COVID-19-focused collaborations.

Private Company Edition: Omega Funds closed its seventh venture capital fund, far exceeding its $500m goal. Also, Anaveon raised a CHF110m ($119.8m) series B round, Ambys brought its series A total to $107m with $47m in additional investment and Mythic launched with a $103m series B round.

With Parkinson's affecting about six million people worldwide – with some estimates putting it as high as 10 million – and the condition becoming increasingly burdensome on health systems around the globe, "we don't have to do a lot of convincing" the disease is worthwhile to invest in and pursue for new treatments, said Todd Sherer, CEO of the Michael J. Fox Foundation (MJFF).